Pyxis Oncology ... to begin patient dosing in Q1 2025. Additionally, the ongoing Phase 1 study is expanding its monotherapy cohorts to include R/M HNSCC patients with specific prior treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback